A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Saved in:
| Title: | A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. |
|---|---|
| Authors: | Collier KA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Valencia H; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Newton H; Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Hade EM; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Cavaliere R; Division Neuro-Oncology, Department of Cancer Medicine, Baptist MD Anderson, Jacksonville, FL, USA., Poi M; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Phelps MA; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Liva SG; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Coss CC; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Wang J; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Khountham S; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Monk P; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Shapiro CL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Piekarz R; National Cancer Institute/Cancer Therapy Evaluation Program, Bethesda, MD, USA., Hofmeister CC; Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA., Welling DB; Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, Boston, MA, USA., Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA. Amir.Mortazavi@osumc.edu. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 May; Vol. 87 (5), pp. 599-611. Date of Electronic Publication: 2021 Jan 25. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-020-04229-3 |
